ArticleTrials2026
REVIVE-HF: rehabilitation with immersive virtual reality and exercise in hospitalized patients with heart failure-a randomized controlled trial protocol.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a chronic condition characterized by significant functional limitations, with exercise intolerance as a major determinant of reduced quality of life. Supervised aerobic exercise is a core intervention in cardiac rehabilitation, yet adherence and tolerance may be hindered by physical and motivational factors. Immersive technologies such as virtual reality (VR) have shown potential to increase engagement and positive perceptions during exercise. This study aims to evaluate the influence of VR on tolerance to cycle-ergometer aerobic exercise in hospitalized patients with HF.
methodsWe will conduct a randomized, controlled, parallel-group trial with 1:1 allocation. Adult inpatients with a diagnosis of HF will be screened for eligibility and randomly assigned to two groups: control (cycle-ergometer aerobic exercise) and intervention (the same exercise combined with an Meta Quest 2 VR device). Each participant will complete a single session of up to 20 min, consisting of five blocks of 3 min of continuous pedaling interspersed with one-minute passive rests, with early termination in case of intolerance. The primary outcome is effective exercise time (minutes) until interruption due to physical limitation or symptoms. Secondary outcomes include rating of perceived exertion, hemodynamic parameters, exercise enjoyment (PACES) and usability of the technology (SUS, intervention group only). DISCUSSION: This study will investigate whether VR can improve tolerance to aerobic exercise during hospitalization for HF, potentially providing preliminary evidence to guide the use of immersive technologies in cardiac rehabilitation. If benefits are observed, VR could be incorporated as a complementary tool to optimize adherence, motivation and safety in supervised exercise programs in this clinical context.
trial registrationThe trial was registered in the Brazilian Clinical Trials Registry (ReBEC), under the identifier RBR-4hrmkzz, on March 11, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.